Caris Life Sciences, Inc. Common Stock (CAI)vsRegeneron Pharmaceuticals Inc (REGN)
CAI
Caris Life Sciences, Inc. Common Stock
$16.49
-4.57%
HEALTHCARE · Cap: $5.08B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1544% more annual revenue ($14.92B vs $907.29M). REGN leads profitability with a 29.6% profit margin vs 3.8%. REGN earns a higher WallStSmart Score of 64/100 (C+).
CAI
Hold44
out of 100
Grade: D
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CAI.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 78.8% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 5.7% — below average capital efficiency
3.8% margin — thin
Operating margin of 2.4%
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Revenue Growth, Debt/Equity. Revenue growth of 78.8% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : CAI
The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
CAI profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
CAI is growing revenue faster at 78.8% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 44/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?